Pharmaceuticals that are particularly created using genetic data from DNA, protein profile, and their functionality while understanding how they interact with human health are known as genomic medicines, also referred to as personal medicine. These medications are able to reveal specifics about a person's usual biological facts, which may then be used to construct the appropriate patient's treatment regimen and pharmaceuticals.
Frequently Asked Questions
The market is segmented based on Segmentation, By Application (Oncology, Cardiology, Paediatrics, Endocrinology, Respiratory Medicine, Rare Genetic Disorders, Infectious Diseases, Others), End- User (Hospitals, Clinics, Academic Institutions, Research Institutions)– Industry Trends and Forecast to 2032
.
The Global Genomic Medicine Market size was valued at USD 36.03 USD Billion in 2024.
The Global Genomic Medicine Market is projected to grow at a CAGR of 16% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
